The Wolverine blend pairs BPC-157 and TB-500 in a single reconstitution — two independent, non-overlapping tissue-research mechanisms in one vial. Full reference: rationale, handling, COA.
The 'Wolverine' blend is the widely-used nickname across research supply for the combination of BPC-157 and TB-500 in a shared vial. The pairing is not arbitrary: both compounds engage independent tissue-research pathways — BPC-157 through VEGFR2 and endothelial nitric-oxide signalling, and TB-500 through direct G-actin sequestration via the LKKTETQ motif — which means concurrent profiling does not confound the interpretation of either endpoint.
This reference explains the mechanistic rationale behind the blend, the practical research advantages of a single-reconstitution format, the stability characteristics shared by both peptides, and the analytical documentation researchers should insist on for a blend COA. All content is research-use-only.
Component reference table
| Component | Class | Primary mechanism | Length |
|---|---|---|---|
| BPC-157 | Gastric-juice fragment peptide | VEGFR2 / NO signalling | 15 residues |
| TB-500 | Thymosin β4 fragment | Actin sequestration (LKKTETQ) | Bioactive fragment of 43-mer |
Why the pairing is mechanistically clean
- Non-overlapping pathways: VEGFR2/NO (BPC-157) and actin sequestration (TB-500) do not share receptors or effectors, so concurrent profiling is interpretable.
- Complementary tissue-research endpoints: vascular / mucosal (BPC-157) and cytoskeletal / migration (TB-500).
- Compatible stability profiles allow a single reconstitution and shared aliquoting.
Practical research advantages of a blend format
- Single reconstitution reduces pipetting variability across concurrent assays.
- Independent mechanisms make additive endpoints easier to interpret.
- Both compounds share compatible short-term stability at 2–8 °C after reconstitution.
- Fewer freeze–thaw cycles per component when working from a single working stock.
What a proper blend COA looks like
A blend COA must report per-component analytical data — never combined mass alone. Insist on HPLC purity per component, quantified peptide content per vial for each peptide independently, and the counterion for each peptide separately (BPC-157 and TB-500 can differ). A blend COA that reports only combined mass is not fit for research documentation.
- HPLC purity ≥98% reported independently for BPC-157 and TB-500.
- LC-MS identity confirmation within ±0.5 Da of theoretical for each peptide.
- Quantified peptide content per vial for each component.
- Counterion identity (acetate vs TFA) reported per component.
- Endotoxin and residual solvent testing per the analytical method.
- Batch identifier traceable to the synthesis and blending record.
Handling & stability
- Store lyophilised blend desiccated at −20 °C, light-protected.
- Reconstitute with bacteriostatic water and store the working stock at 2–8 °C for short-term assay use.
- Aliquot on reconstitution; avoid repeated freeze–thaw of the reconstituted blend.
What is the Wolverine peptide blend?
The Wolverine blend is the widely-used nickname for a combined BPC-157 + TB-500 research vial. It pairs two peptides with independent, non-overlapping tissue-research mechanisms in a single reconstitution.
Why are BPC-157 and TB-500 blended together?
Because their mechanisms are independent — VEGFR2/NO signalling (BPC-157) and actin sequestration (TB-500) — concurrent profiling in tissue-research models does not confound the interpretation of either endpoint. The blend format also simplifies reconstitution and aliquoting.
What should a Wolverine blend COA include?
Per-component reporting: HPLC purity ≥98% for each peptide independently, LC-MS identity within ±0.5 Da of theoretical for each, quantified peptide content per vial per component, counterion identity per component, endotoxin and residual solvent testing, and batch traceability. Reject any COA that reports only combined mass.
How is the Wolverine blend stored?
Lyophilised blend is stored desiccated at −20 °C, light-protected. Reconstituted with bacteriostatic water, the working stock is typically kept at 2–8 °C for short-term assay use, with aliquoting on reconstitution to avoid freeze–thaw.
Is the Wolverine blend a single peptide?
No. It is a physical combination of two distinct peptides (BPC-157 and TB-500) in a shared vial, not a chimeric or fusion peptide. Each component retains its own sequence, mass and mechanism.
Is the Wolverine blend approved for human use in New Zealand?
No. Neither BPC-157 nor TB-500 is an approved therapeutic in New Zealand. The blend is supplied strictly as a research-use-only reference material for in-vitro laboratory work.
